Zografos L - Search Results

1

Eye retention after proton beam radiotherapy for uveal melanoma.

Egger E, Zografos L, Schalenbourg A, Beati D, Böhringer T, Chamot L, Goitein G. Egger E, et al. Among authors: zografos l. Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):867-80. doi: 10.1016/s0360-3016(02)04200-1. Int J Radiat Oncol Biol Phys. 2003. PMID: 12605964 Review.

2

Metastatic melanoma in the eye and orbit.

Zografos L, Ducrey N, Beati D, Schalenbourg A, Spahn B, Balmer A, Othenin-Girard CB, Chamot L, Egger E. Zografos L, et al. Ophthalmology. 2003 Nov;110(11):2245-56. doi: 10.1016/j.ophtha.2003.05.004. Ophthalmology. 2003. PMID: 14597536

3

Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.

Petrovic A, Bergin C, Schalenbourg A, Goitein G, Zografos L. Petrovic A, et al. Among authors: zografos l. Ophthalmology. 2014 Apr;121(4):898-904. doi: 10.1016/j.ophtha.2013.10.032. Epub 2014 Jan 7. Ophthalmology. 2014. PMID: 24405742 Free article.

4

Results of proton radiotherapy for uveal melanomas.

Egger E, Zografos L, Munkel G, Böhringer T, Bercher L, Chamot L. Egger E, et al. Among authors: zografos l. Front Radiat Ther Oncol. 1997;30:111-22. doi: 10.1159/000425694. Front Radiat Ther Oncol. 1997. PMID: 9205891 No abstract available.

5

Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.

Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, Goitein G. Egger E, et al. Among authors: zografos l. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):138-47. doi: 10.1016/s0360-3016(01)01560-7. Int J Radiat Oncol Biol Phys. 2001. PMID: 11516863

6

Systemic melanoma metastatic to the retina and vitreous.

Zografos L, Mirimanoff RO, Angeletti CA, Frosini R, Beati D, Schalenbourg A, Chamot L. Zografos L, et al. Ophthalmologica. 2004 Nov-Dec;218(6):424-33. doi: 10.1159/000080948. Ophthalmologica. 2004. PMID: 15564763 Review.

7

Melanocytomas of the optic disk.

Zografos L, Othenin-Girard CB, Desjardins L, Schalenbourg A, Chamot L, Uffer S. Zografos L, et al. Am J Ophthalmol. 2004 Dec;138(6):964-9. doi: 10.1016/j.ajo.2004.07.004. Am J Ophthalmol. 2004. PMID: 15629287

8

Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.

Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S. Voelter V, et al. Among authors: zografos l. Melanoma Res. 2008 Jun;18(3):220-4. doi: 10.1097/CMR.0b013e32830317de. Melanoma Res. 2008. PMID: 18477897 Clinical Trial.

9

Role of vitreoretinal surgery in maximizing treatment outcome following complications after proton therapy for uveal melanoma.

Tran BK, Schalenbourg A, Bovey E, Zografos L, Wolfensberger TJ. Tran BK, et al. Among authors: zografos l. Retina. 2013 Oct;33(9):1777-83. doi: 10.1097/IAE.0b013e318295f758. Retina. 2013. PMID: 23792487

10

Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma.

Mantel I, Schalenbourg A, Bergin C, Petrovic A, Weber DC, Zografos L. Mantel I, et al. Among authors: zografos l. Am J Ophthalmol. 2014 Oct;158(4):693-701.e2. doi: 10.1016/j.ajo.2014.07.002. Epub 2014 Jul 14. Am J Ophthalmol. 2014. PMID: 25034116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217 results

Search Page